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Background. Surgical resection is a universal component of glioma therapy. Little is known about the postoperative microenviron-
ment due to limited preclinical models. Thus, we sought to develop a glioma resection and recurrence model in syngeneic
immune-competent mice to understand how surgical resection influences tumor biology and the local microenvironment.
Methods.We genetically engineered cells from a murine glioma mouse model to express fluorescent and bioluminescent report-
ers. Established allografts were resected using image-guided microsurgery. Postoperative tumor recurrence was monitored by
serial imaging, and the peritumoral microenvironment was characterized by histopathology and immunohistochemistry. Cocul-
ture techniques were used to explore how astrocyte injury influences tumor aggressiveness in vitro. Transcriptome and secretome
alterations in injured astrocytes was examined by RNA-seq and Luminex.
Results. We found that image-guided resection achieved .90% reduction in tumor volume but failed to prevent both local and
distant tumor recurrence. Immunostaining for glial fibrillary acidic protein and nestin showed that resection-induced injury led to
temporal and spatial alterations in reactive astrocytes within the peritumoral microenvironment. In vitro, we found that astrocyte
injury induced transcriptome and secretome alterations and promoted tumor proliferation, as well as migration.
Conclusions. This study demonstrates a unique syngeneic model of glioma resection and recurrence in immune-competent mice.
Furthermore, this model provided insights into the pattern of postsurgical tumor recurrence and changes in the peritumoral microen-
vironment, aswell as the impact of injured astrocytes on glioma growth and invasion. A better understanding of the postsurgical tumor
microenvironment will allow development of targeted anticancer agents that improve surgery-mediated effects on tumor biology.
Keywords: glioblastoma, glioma, migration, reactive astrocytosis, recurrence.
Glioblastoma (GBM) is the most prevalent and aggressive pri-
mary brain tumor and portends a poor prognosis.1,2 The current
clinical treatment regimen involves surgical resection followed
by chemo- and radiotherapy.3–5However, these treatments fail
to prevent tumor recurrence, and median survival remains only
12–15 months.3,6 As surgical resection is central to clinical
care, a clear understanding of the postsurgical environment
and the role that surgery-induced changes play in mediating
tumor response to treatment is vital. It is known that resection
mediates pathological changes to residual tumor cells that in-
clude increased proliferation as well as enhanced invasion.7,8
Additionally, surgery-related changes to the tumor microenvi-
ronment have been implicated in reduced effectiveness of
local intracavity chemotherapy.9 Temporal analysis of clinical
tissue samples would facilitate the study of these phenomena,
yet the rates of surgery-related mortality are low for brain can-
cer patients, and few clinical tissue samples are available for
analysis.10 This makes the use of animal models a necessity,
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but the mainstay of preclinical GBM models remains solid
orthotopic human xenografts that fail to incorporate surgical
tumor resection.11 Thus, preclinical models of GBM resection/
recurrence are needed to understand the postoperative
tumor environment and how it may contribute to tumor pro-
gression, regrowth, or treatment failure.
Previously, we created an image-guided surgical model of
glioma resection and recurrence in mice.8,9 In this model, sur-
gical resection of intracranial human GBM xenografts is guided
by intraoperative fluorescence imaging. Pre- and postoperative
multimodality imaging revealed that this approach allowed re-
moval of �92% of the primary mass, followed by rapid recur-
rence of residual GBM cells that displayed a faster growth rate
and altered blood-vessel density compared with nonresected
tumors. Although beneficial, this model fails to address several
key aspects of clinical GBM resection. First, the use of human
xenografts in immune-depleted animals has left the role of the
immune system entirely unexplored. Immune cells within the
tumor microenvironment are known to release soluble factors
that regulate GBM growth, migration, and angiogenesis.12 –14
After treatment, tumor cells are thought to hijack components
of the host immune system and utilize these cells to mediate re-
sistance to chemotherapy and apoptosis, increasing malignant
tumor progression.15,16 Secondly, our initial studies employed
U87 and other established GBM cell lines. While the genetics of
these extensively cultured cells vastly differ from their surgical
counterparts, these lines also fail to recapitulate many histolog-
ical hallmarks of GBM, such as the infiltrative growth pattern ob-
served in human patients.11,17
We have recently described a new genetically engineered
murinemodel of GBM in which key signaling pathways were tar-
geted specifically to astrocytes.18–20 These tumor cells, which
we call TRP, were transformed from cultured astrocytes by in-
ducing aberrations in 3 of the most commonly mutated GBM
networks by inactivating the retinoblastoma protein family of
G1/S cell cycle proteins (T), activating the Kirsten rat sarcoma
viral oncogene homolog (R), and inactivating the phosphatase
and tensin homolog tumor suppressor gene (P). Injection of TRP
astrocytes into syngeneic, immune-competent hosts generates
GBM that exhibits infiltrative growth patterns and recapitulates
aspects of the clinical disease. Engineered TRP allograft models
accurately recapitulate the full range of histological traits seen
in clinical GBM, including elevated mitotic activity, microvascu-
lar proliferation, and necrosis. Inoculation of TRP within an
immune-competent host enables both the innate and acquired
immune systems present to interact with the tumor microenvi-
ronment, features that cannot be recapitulated in immune-
depleted human xenograft models. Together, these features
suggest that image-guided microsurgery of TRP allografts
could be used to develop more accurate models of GBM.
In this study, we utilized TRP astrocytes to create a novel
model of GBM resection/recurrence in immune-competent
hosts and sought to characterize the key pathological features
of the postoperative surgical cavity. We engineered the TRP
model system with optical reporters to allow for microsurgical
visualization, real-time monitoring of tumor growth, and as-
sessment of the biological consequences of tumor resection.
We used bioluminescence imaging and histology to monitor
the pattern of postsurgical tumor recurrence, with a specific
focus on local tumor growth within the resection cavity, as
well as distant growth by invasive tumor cells. Finally, we used
immunohistochemistry and in vitro coculture techniques to in-
vestigate dynamic changes in the reactive astrocyte component
of the tumor microenvironment. We found that surgery induces
a phenotypic switch in reactive astrocytes into a more primitive
cell type. Using a model that mimics the in vivo astrocyte re-
sponse to surgical trauma and astrocytes isolated from the in
vivo resection model, we found that injury to astrocytes pro-
motes tumor proliferation and migration in vitro. Additionally,
through transcriptome and secretome analysis, we revealed
that Cxcl5 may play a key role in this effect. This suggests that
traumatic brain injury induced by tumor resection alters the
local microenvironment and that injured astrocytes may impact
the aggressiveness of GBM cells adjacent to the surgical cavity.
Materials and Methods
Cell Culture
TRP, GL261, U251, and U87 cells were cultured at 378C and 5%
CO2 in complete medium consisting of Dulbecco’s modified
Eagle’s medium (Gibco) with 10% fetal bovine serum (Sigma)
and penicillin/streptomycin (100 mg/mL; Sigma), as described.20
Fluorescent-Guided Microsurgical Resection
TRP–mCherry-FLuc (mcF) allografts were formed by intracranial
tumor inoculation in C57BL/6 mice and established for 14 days.
Cranial windowswere created to aid visualization of fluorescent
tumor and allow for tumor removal. TRP-mcF allografts were
surgically excised under fluorescence microscopy using a com-
bination of aspiration and microsurgical dissection. Biolumines-
cent imaging (BLI) was used pre-resection, immediately
post-resection, and at serial time points postsurgery to deter-
mine extent of resection and growth of recurrent tumors. Post-
surgical mouse brains harvested at various time points were
characterized using histology and immunohistochemistry to
observe patterns of tumor recurrence and determine patholog-
ical consequences of resection. Animal studies were approved
by the University of North Carolina Institutional Animal Care
and Use Committee.
Cell Growth and Migration In vitro
Glioma cells (TRP-mcF, GL261, U87, U251), immortalized astro-
cytes, and astrocytes derived from the in vivo resection model
were seeded separately into adjacent wells located 0.5 mm
apart in 2-chamber culture inserts (Ibidi), placed in microwell dish-
es (MatTek) or 24-well plates, and incubated overnight in complete
media. Culture inserts were removed and astrocytes were either
scratch injured or left uninjured. Cells were imaged over 24 h for
migration. To assess proliferation, 5-ethynyl-2′-deoxyuridine
(EdU) was pulsed into culture medium at 24 h for 2 h. ImageJ
was used to perform analysis.
To assess proliferation of TRP-mcF cells by bioluminescence,
immortalized astrocytes were grown in 24-well plates, and
cells were either scratched or left untreated. Twenty-four
hours later, the scratch astrocyte conditioned medium (SACM)
or control astrocyte conditioned medium (ACM) was collected.
Cell proliferation was measured by BLI using an IVIS Kinetic
(PerkinElmer).
Okolie et al.: Reactive astrocytes potentiate glioma recurrence
2 of 12 Neuro-Oncology
Neuro-Oncology 1623
Okolie et al.: Reactive astrocytes potentiate glioma recurrence
Reactive astrocytes potentiate tumor aggressiveness in a murine
glioma resection and recurrence model
Onyinyechukwu Okolie, Juli R. Bago, Ralf S. Schmid, David M. Irvin, Ryan E. Bash, C. Ryan Miller†,
and Shawn D. Hingtgen†
Division of Molecular Pharmaceutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill,
North Carolina (O.O., J.R.B., S.D.H.); Division of Neuropathology, Department of Pathology and Laboratory Medicine, Department of
Neurology, and Neuroscience Center, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina (C.R.M.);
Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina (R.S.S., D.M.I., R.E.B.,
C.R.M., S.D.H.); Biomedical Research Imaging Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina (S.D.H.)
Corresponding Authors: C. Ryan Miller, MD, PhD, University of North Carolina School of Medicine, 6109B Neurosciences Research Building, Chapel
Hill, NC 27599 (rmiller@med.unc.edu); Shawn D. Hingtgen, PhD, University of North Carolina Eshelman School of Pharmacy, 4212 Marsico Hall, 125
Mason Farm Road, Chapel Hill, NC 27599 (hingtgen@email.unc.edu).
†These authors contributed equally to this work.
Background. Surgical resection is a universal component of glioma therapy. Little is known about the postoperative microenviron-
ment due to limited preclinical models. Thus, we sought to develop a glioma resection and recurrence model in syngeneic
immune-competent mice to understand how surgical resection influences tumor biology and the local microenvironment.
Methods.We genetically engineered cells from a murine glioma mouse model to express fluorescent and bioluminescent report-
ers. Established allografts were resected using image-guided microsurgery. Postoperative tumor recurrence was monitored by
serial imaging, and the peritumoral microenvironment was characterized by histopathology and immunohistochemistry. Cocul-
ture techniques were used to explore how astrocyte injury influences tumor aggressiveness in vitro. Transcriptome and secretome
alterations in injured astrocytes was examined by RNA-seq and Luminex.
Results. We found that image-guided resection achieved .90% reduction in tumor volume but failed to prevent both local and
distant tumor recurrence. Immunostaining for glial fibrillary acidic protein and nestin showed that resection-induced injury led to
temporal and spatial alterations in reactive astrocytes within the peritumoral microenvironment. In vitro, we found that astrocyte
injury induced transcriptome and secretome alterations and promoted tumor proliferation, as well as migration.
Conclusions. This study demonstrates a unique syngeneic model of glioma resection and recurrence in immune-competent mice.
Furthermore, this model provided insights into the pattern of postsurgical tumor recurrence and changes in the peritumoral microen-
vironment, aswell as the impact of injured astrocytes on glioma growth and invasion. A better understanding of the postsurgical tumor
microenvironment will allow development of targeted anticancer agents that improve surgery-mediated effects on tumor biology.
Keywords: glioblastoma, glioma, migration, reactive astrocytosis, recurrence.
Glioblastoma (GBM) is the most prevalent and aggressive pri-
mary brain tumor and portends a poor prognosis.1,2 The current
clinical treatment regimen involves surgical resection followed
by chemo- and radiotherapy.3–5However, these treatments fail
to prevent tumor recurrence, and median survival remains only
12–15 months.3,6 As surgical resection is central to clinical
care, a clear understanding of the postsurgical environment
and the role that surgery-induced changes play in mediating
tumor response to treatment is vital. It is known that resection
mediates pathological changes to residual tumor cells that in-
clude increased proliferation as well as enhanced invasion.7,8
Additionally, surgery-related changes to the tumor microenvi-
ronment have been implicated in reduced effectiveness of
local intracavity chemotherapy.9 Temporal analysis of clinical
tissue samples would facilitate the study of these phenomena,
yet the rates of surgery-related mortality are low for brain can-
cer patients, and few clinical tissue samples are available for
analysis.10 This makes the use of animal models a necessity,
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but the mainstay of preclinical GBM models remains solid
orthotopic human xenografts that fail to incorporate surgical
tumor resection.11 Thus, preclinical models of GBM resection/
recurrence are needed to understand the postoperative
tumor environment and how it may contribute to tumor pro-
gression, regrowth, or treatment failure.
Previously, we created an image-guided surgical model of
glioma resection and recurrence in mice.8,9 In this model, sur-
gical resection of intracranial human GBM xenografts is guided
by intraoperative fluorescence imaging. Pre- and postoperative
multimodality imaging revealed that this approach allowed re-
moval of �92% of the primary mass, followed by rapid recur-
rence of residual GBM cells that displayed a faster growth rate
and altered blood-vessel density compared with nonresected
tumors. Although beneficial, this model fails to address several
key aspects of clinical GBM resection. First, the use of human
xenografts in immune-depleted animals has left the role of the
immune system entirely unexplored. Immune cells within the
tumor microenvironment are known to release soluble factors
that regulate GBM growth, migration, and angiogenesis.12 –14
After treatment, tumor cells are thought to hijack components
of the host immune system and utilize these cells to mediate re-
sistance to chemotherapy and apoptosis, increasing malignant
tumor progression.15,16 Secondly, our initial studies employed
U87 and other established GBM cell lines. While the genetics of
these extensively cultured cells vastly differ from their surgical
counterparts, these lines also fail to recapitulate many histolog-
ical hallmarks of GBM, such as the infiltrative growth pattern ob-
served in human patients.11,17
We have recently described a new genetically engineered
murinemodel of GBM in which key signaling pathways were tar-
geted specifically to astrocytes.18–20 These tumor cells, which
we call TRP, were transformed from cultured astrocytes by in-
ducing aberrations in 3 of the most commonly mutated GBM
networks by inactivating the retinoblastoma protein family of
G1/S cell cycle proteins (T), activating the Kirsten rat sarcoma
viral oncogene homolog (R), and inactivating the phosphatase
and tensin homolog tumor suppressor gene (P). Injection of TRP
astrocytes into syngeneic, immune-competent hosts generates
GBM that exhibits infiltrative growth patterns and recapitulates
aspects of the clinical disease. Engineered TRP allograft models
accurately recapitulate the full range of histological traits seen
in clinical GBM, including elevated mitotic activity, microvascu-
lar proliferation, and necrosis. Inoculation of TRP within an
immune-competent host enables both the innate and acquired
immune systems present to interact with the tumor microenvi-
ronment, features that cannot be recapitulated in immune-
depleted human xenograft models. Together, these features
suggest that image-guided microsurgery of TRP allografts
could be used to develop more accurate models of GBM.
In this study, we utilized TRP astrocytes to create a novel
model of GBM resection/recurrence in immune-competent
hosts and sought to characterize the key pathological features
of the postoperative surgical cavity. We engineered the TRP
model system with optical reporters to allow for microsurgical
visualization, real-time monitoring of tumor growth, and as-
sessment of the biological consequences of tumor resection.
We used bioluminescence imaging and histology to monitor
the pattern of postsurgical tumor recurrence, with a specific
focus on local tumor growth within the resection cavity, as
well as distant growth by invasive tumor cells. Finally, we used
immunohistochemistry and in vitro coculture techniques to in-
vestigate dynamic changes in the reactive astrocyte component
of the tumor microenvironment. We found that surgery induces
a phenotypic switch in reactive astrocytes into a more primitive
cell type. Using a model that mimics the in vivo astrocyte re-
sponse to surgical trauma and astrocytes isolated from the in
vivo resection model, we found that injury to astrocytes pro-
motes tumor proliferation and migration in vitro. Additionally,
through transcriptome and secretome analysis, we revealed
that Cxcl5 may play a key role in this effect. This suggests that
traumatic brain injury induced by tumor resection alters the
local microenvironment and that injured astrocytes may impact
the aggressiveness of GBM cells adjacent to the surgical cavity.
Materials and Methods
Cell Culture
TRP, GL261, U251, and U87 cells were cultured at 378C and 5%
CO2 in complete medium consisting of Dulbecco’s modified
Eagle’s medium (Gibco) with 10% fetal bovine serum (Sigma)
and penicillin/streptomycin (100 mg/mL; Sigma), as described.20
Fluorescent-Guided Microsurgical Resection
TRP–mCherry-FLuc (mcF) allografts were formed by intracranial
tumor inoculation in C57BL/6 mice and established for 14 days.
Cranial windowswere created to aid visualization of fluorescent
tumor and allow for tumor removal. TRP-mcF allografts were
surgically excised under fluorescence microscopy using a com-
bination of aspiration and microsurgical dissection. Biolumines-
cent imaging (BLI) was used pre-resection, immediately
post-resection, and at serial time points postsurgery to deter-
mine extent of resection and growth of recurrent tumors. Post-
surgical mouse brains harvested at various time points were
characterized using histology and immunohistochemistry to
observe patterns of tumor recurrence and determine patholog-
ical consequences of resection. Animal studies were approved
by the University of North Carolina Institutional Animal Care
and Use Committee.
Cell Growth and Migration In vitro
Glioma cells (TRP-mcF, GL261, U87, U251), immortalized astro-
cytes, and astrocytes derived from the in vivo resection model
were seeded separately into adjacent wells located 0.5 mm
apart in 2-chamber culture inserts (Ibidi), placed in microwell dish-
es (MatTek) or 24-well plates, and incubated overnight in complete
media. Culture inserts were removed and astrocytes were either
scratch injured or left uninjured. Cells were imaged over 24 h for
migration. To assess proliferation, 5-ethynyl-2′-deoxyuridine
(EdU) was pulsed into culture medium at 24 h for 2 h. ImageJ
was used to perform analysis.
To assess proliferation of TRP-mcF cells by bioluminescence,
immortalized astrocytes were grown in 24-well plates, and
cells were either scratched or left untreated. Twenty-four
hours later, the scratch astrocyte conditioned medium (SACM)
or control astrocyte conditioned medium (ACM) was collected.
Cell proliferation was measured by BLI using an IVIS Kinetic
(PerkinElmer).
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Fluorescence Immunocytochemistry In vitro
To investigate the impact of astrocyte injury on nestin and glial
fibrillary acidic protein (GFAP) expression in vitro, immortalized
astrocytes were seeded in 24-well plates. Cells were formalin
fixed and incubated with GFAP or nestin primary antibodies
and dye-conjugated secondary antibodies as previously
described.21
Bioluminescent Imaging and Survival Analysis
Pre-resection tumor volumes were monitored by BLI using an
IVIS Kinetic. Surgery was performed on day 14 and tumor re-
currence was monitored. Mice were monitored for neurological
symptoms and sacrificed upon their development. Survival
analysis was performed as previously described.8
Histopathology and Immunohistochemistry
Allograft mice were resected at day 14 after cell injection and
randomized for sacrifice at days 1, 3, 5, and 7 post-resection.
Formalin-fixed, paraffin-embedded brain sections were stained
with hematoxylin and eosin (H&E), and Iba-1 immunohisto-
chemistry was performed as previously described.22
RNA-Seq Analyses
Total RNAwas extracted from injured or uninjured astrocyte cell
pellets using the Qiagen RNeasy kit, followed by library prepa-
ration using a Stranded mRNA-seq Kit (Kapa Biosystems) ac-
cording to the manufacturer’s instructions. High-throughput
sequencing with 75-bp single-end reads was performed on a
NextSeq500 using the Illumina High Output Kit and analyzed
as previously described.23,24
Luminex Analysis
Protein levels in the supernatant of injured or uninjured astro-
cytes were determined using a mouse magnetic Luminex
screening assay (R&D Systems) according to the manufactur-
er’s protocol. Each sample was prepared in a 24-well plate as
described above. Medium from each well was collected and
used for protein analysis.
Supplementary Materials
Additional materials and methods are detailed in the Supple-
ment. Supplementary figures and videos can also be found
online.
Results
Fluorescence-Guided Microsurgery Effectively Reduces
Orthotopic TRP Allograft Burden but Fails to Prevent Rapid
Tumor Recurrence
We infected murine TRP cells with a recombinant lentiviral vec-
tor encoding mcF (TRP-mcF) to facilitate high-resolution fluo-
rescence imaging–guided microsurgical tumor resection and
noninvasive BLI to quantify tumor volumes (Fig. 1A–D). Fluo-
rescence imaging confirmed mCherry expression (Fig. 1B and
D). TRP-mcF cells showed a small but statistically significant
decrease in growth compared with uninfected TRP cells
(Fig. 1E). Dilution assays revealed that the luciferase activity
of TRP-mcF correlated directly with cell number in vitro (Fig. 1F).
We have previously shown that TRP allografts develop the
histopathological hallmarks of human gliomas18 and progress
to GBM 15–20 days after orthotopic cell injection.20 Similar to
the parental line, serial BLI showed that engineered TRP-mcF
allografts developed into rapidly expanding tumors over 24
days in the parenchyma of C57BL/6mice (Fig. 1G). Fluorescence
and histological analysis of postmortem tissue sections con-
firmed the presence of large TRP-mcF tumors 14 days after in-
jection (Fig. 1H and I). These tumors contained abundant
microvascular proliferation and elevated mitotic activity
(Fig. 1J–M) but generally lacked necrosis at this time point.
These results demonstrate that TRP glioma cells engineered
to express mCherry and luciferase develop the histopathologi-
cal hallmarks of human GBM.
Our previous microsurgical resection model using U87 cells
failed to recapitulate important hallmarks of clinical GBM,
including a full immune system and brain invasion.8 We
have previously shown that TRP-mcF allografts diffusely
invade the brain parenchyma when established in syngeneic,
immunocompetent mice.20 We therefore examined whether
fluorescence-guided microsurgery could be used to resect
TRP-mcF allografts that accurately reflect the brain-invasive
phenotype of human GBM in immune-competent C57 hosts.
Fourteen days after intracortical injection of TRP-mcF cells,
mCherry fluorescence was evident in the surgical field and
was used to guide microsurgical dissection (Fig. 2A–D). Pre-
and postoperative BLI showed that resection achieved .90%
reduction in tumor burden (Fig. 2E). Histological analysis con-
firmed these findings, as most mice examined displayed only
small residual deposits of tumor remaining near the resection
cavity on postoperative day 1 (Fig. 2F and G).
To examine the therapeutic benefit of resection, we moni-
tored TRP-mcF growth before and after surgery using BLI. Inter-
estingly, recurrent TRP-mcF tumors grew more rapidly than
their pre-resection counterparts (Fig. 2H). Similar to clinical
findings, resected mice survived significantly longer than non-
resected mice but eventually succumbed from their tumor
(Fig. 2I).10,25,26 Fluorescence imaging and histological examina-
tion of symptomatic, terminally aged mice confirmed the pres-
ence of recurrent mCherry+ tumors around the resection cavity
(Fig. 2J and K). Taken together, these results demonstrate that
fluorescence-guided microsurgery can be used to create a TRP
allograft resection and recurrence model in a syngeneic
immune-competent host where surgery extends the life of
mice, but tumor recurrence eventually leads to death.
We next characterized the peritumoral microenvironment
by performing histological analysis of tumor brains 1–7 days
after resection to monitor patterns of postsurgical recurrence.
Histology confirmed near-total tumor resection 1–3 days after
microsurgery (Fig. 3A–H). However, despite absence of tumor
at the resection cavity, tumor invasion of the deep ipsilateral
hemisphere led to distant recurrence (Fig. 3I). Recurrent, mitot-
ically active (Fig. 3J) tumors exhibited extensive migration
along blood vessels (Fig. 3K) and diffusely invaded brain paren-
chyma (Fig. 3L). Five days after tumor microsurgery, locally re-
current tumor became apparent near the resection cavity
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(Fig. 3M) and was accompanied by reactive changes in the re-
section bed, including hemosiderin-laden macrophages and re-
active astrocytes (Fig. 3N–P). After 7 days, locally recurrent
tumors became large, highly mitotically active, and necrotic
(Fig. 3Q–T) and diffusely invaded the adjacent brain. Local
tumor recurrence was accompanied by increased reactive
changes in the resection bed, including infiltration of foamy
and hemosiderin-ladenmacrophages (Fig. 3U–X). These results
suggest that fluorescence-aided microsurgery in the syngeneic
TRP-mcF allograft model system recapitulates aspects of clini-
cal GBM, including invasion and distant recurrence, a process
that occurs concomitantly with reactive, surgery-induced
changes in the resection cavity.
Microsurgery Induces Dynamic Changes in the Reactive
Astrocyte Component of the Peritumoral
Microenvironment Surrounding TRP-mcF Allografts
Reactive astrocytes are the main cellular component of glial
scars that develop in response to a variety of pathological stim-
uli in the brain. During tumorigenesis, these cells play a key role
in tumor progression and invasion,13,27–30 where they develop
hypertrophic cytoplasmic processes and upregulate expression
of cytoskeletal proteins such as GFAP. Indeed, hypertrophic
GFAP+ reactive astrocytes accumulated near the invasive
edge of TRP-mcF allografts and became progressively dense
as these tumors grew (Fig. 4A and B).
In addition to tumorigenesis, reactive astrocytes are a signif-
icant component of the glial scars that develop in response to
blunt force brain trauma.31–35 In murine models, stab wound
injury induces proliferation of GFAP+ reactive astrocytes that
also express stem cell markers, such as the intermediate fila-
ment nestin.34,36 –38 Moreover, these cells have been shown
to acquire the phenotypic properties of stem cells when cul-
tured ex vivo, including unlimited self-renewal andmultilineage
differentiation.36,37 To determine whether the reactive astro-
cytes that accompanied TRP-mcF allograft growth might un-
dergo a similar change in phenotype, we performed nestin
immunostaining on established tumors. In contrast to their
abundant GFAP immunoreactivity, reactive astrocytes around
the invasive edge of TRP-mcF allografts did not express nestin,
suggesting they lacked stemlike properties (Fig. 4C).
To examine the effects of blunt force trauma induced by mi-
crosurgical resection on reactive astrocytes in the peritumoral
Fig. 1. TRP cells engineered to express mCherry and luciferase proliferate in vitro and form GBM allografts in vivo. Cultured TRP glioma cells
transduced with lentiviral vectors encoding TRP-mcF express mCherry and luciferase in vitro as determined by (A and C) white light and (B and
D) fluorescence imaging. TRP-mcF cells (doubling time 1.1 days) showed a small but statistically significant decrease in growth compared with
uninfected TRP cells (doubling time 0.9 days, P¼ .01) (E). TRP-mcF cell number showed linear correlation with Fluc activity (R2¼ .998, P,
.0001) (F). TRP-mcF allografts showed exponential growth with a doubling time of 3.3 days in vivo by BLI (G). Representative H&E staining (H
and J–M) and mCherry fluorescence imaging (I) of brain sections show large intracortical tumors 14 days after injection of TRP-mcF cells.
Tumors showed histopathological features of GBM, including microvascular proliferation (black arrowheads), an invasive brain-tumor interface
(white arrow), and elevated mitotic activity (white arrowheads). Original magnifications: 15x (H and I), 40x (A and B), 100x (C, D, and J), 200x
(K), 400x (L), and 600x (M). Scale bars, 100 mm (A–D) and 200 mm (J–M).
Okolie et al.: Reactive astrocytes potentiate glioma recurrence
4 of 12 Neuro-Oncology
Neuro-Oncology 1625
Okolie et al.: Reactive astrocytes potentiate glioma recurrence
Fluorescence Immunocytochemistry In vitro
To investigate the impact of astrocyte injury on nestin and glial
fibrillary acidic protein (GFAP) expression in vitro, immortalized
astrocytes were seeded in 24-well plates. Cells were formalin
fixed and incubated with GFAP or nestin primary antibodies
and dye-conjugated secondary antibodies as previously
described.21
Bioluminescent Imaging and Survival Analysis
Pre-resection tumor volumes were monitored by BLI using an
IVIS Kinetic. Surgery was performed on day 14 and tumor re-
currence was monitored. Mice were monitored for neurological
symptoms and sacrificed upon their development. Survival
analysis was performed as previously described.8
Histopathology and Immunohistochemistry
Allograft mice were resected at day 14 after cell injection and
randomized for sacrifice at days 1, 3, 5, and 7 post-resection.
Formalin-fixed, paraffin-embedded brain sections were stained
with hematoxylin and eosin (H&E), and Iba-1 immunohisto-
chemistry was performed as previously described.22
RNA-Seq Analyses
Total RNAwas extracted from injured or uninjured astrocyte cell
pellets using the Qiagen RNeasy kit, followed by library prepa-
ration using a Stranded mRNA-seq Kit (Kapa Biosystems) ac-
cording to the manufacturer’s instructions. High-throughput
sequencing with 75-bp single-end reads was performed on a
NextSeq500 using the Illumina High Output Kit and analyzed
as previously described.23,24
Luminex Analysis
Protein levels in the supernatant of injured or uninjured astro-
cytes were determined using a mouse magnetic Luminex
screening assay (R&D Systems) according to the manufactur-
er’s protocol. Each sample was prepared in a 24-well plate as
described above. Medium from each well was collected and
used for protein analysis.
Supplementary Materials
Additional materials and methods are detailed in the Supple-
ment. Supplementary figures and videos can also be found
online.
Results
Fluorescence-Guided Microsurgery Effectively Reduces
Orthotopic TRP Allograft Burden but Fails to Prevent Rapid
Tumor Recurrence
We infected murine TRP cells with a recombinant lentiviral vec-
tor encoding mcF (TRP-mcF) to facilitate high-resolution fluo-
rescence imaging–guided microsurgical tumor resection and
noninvasive BLI to quantify tumor volumes (Fig. 1A–D). Fluo-
rescence imaging confirmed mCherry expression (Fig. 1B and
D). TRP-mcF cells showed a small but statistically significant
decrease in growth compared with uninfected TRP cells
(Fig. 1E). Dilution assays revealed that the luciferase activity
of TRP-mcF correlated directly with cell number in vitro (Fig. 1F).
We have previously shown that TRP allografts develop the
histopathological hallmarks of human gliomas18 and progress
to GBM 15–20 days after orthotopic cell injection.20 Similar to
the parental line, serial BLI showed that engineered TRP-mcF
allografts developed into rapidly expanding tumors over 24
days in the parenchyma of C57BL/6mice (Fig. 1G). Fluorescence
and histological analysis of postmortem tissue sections con-
firmed the presence of large TRP-mcF tumors 14 days after in-
jection (Fig. 1H and I). These tumors contained abundant
microvascular proliferation and elevated mitotic activity
(Fig. 1J–M) but generally lacked necrosis at this time point.
These results demonstrate that TRP glioma cells engineered
to express mCherry and luciferase develop the histopathologi-
cal hallmarks of human GBM.
Our previous microsurgical resection model using U87 cells
failed to recapitulate important hallmarks of clinical GBM,
including a full immune system and brain invasion.8 We
have previously shown that TRP-mcF allografts diffusely
invade the brain parenchyma when established in syngeneic,
immunocompetent mice.20 We therefore examined whether
fluorescence-guided microsurgery could be used to resect
TRP-mcF allografts that accurately reflect the brain-invasive
phenotype of human GBM in immune-competent C57 hosts.
Fourteen days after intracortical injection of TRP-mcF cells,
mCherry fluorescence was evident in the surgical field and
was used to guide microsurgical dissection (Fig. 2A–D). Pre-
and postoperative BLI showed that resection achieved .90%
reduction in tumor burden (Fig. 2E). Histological analysis con-
firmed these findings, as most mice examined displayed only
small residual deposits of tumor remaining near the resection
cavity on postoperative day 1 (Fig. 2F and G).
To examine the therapeutic benefit of resection, we moni-
tored TRP-mcF growth before and after surgery using BLI. Inter-
estingly, recurrent TRP-mcF tumors grew more rapidly than
their pre-resection counterparts (Fig. 2H). Similar to clinical
findings, resected mice survived significantly longer than non-
resected mice but eventually succumbed from their tumor
(Fig. 2I).10,25,26 Fluorescence imaging and histological examina-
tion of symptomatic, terminally aged mice confirmed the pres-
ence of recurrent mCherry+ tumors around the resection cavity
(Fig. 2J and K). Taken together, these results demonstrate that
fluorescence-guided microsurgery can be used to create a TRP
allograft resection and recurrence model in a syngeneic
immune-competent host where surgery extends the life of
mice, but tumor recurrence eventually leads to death.
We next characterized the peritumoral microenvironment
by performing histological analysis of tumor brains 1–7 days
after resection to monitor patterns of postsurgical recurrence.
Histology confirmed near-total tumor resection 1–3 days after
microsurgery (Fig. 3A–H). However, despite absence of tumor
at the resection cavity, tumor invasion of the deep ipsilateral
hemisphere led to distant recurrence (Fig. 3I). Recurrent, mitot-
ically active (Fig. 3J) tumors exhibited extensive migration
along blood vessels (Fig. 3K) and diffusely invaded brain paren-
chyma (Fig. 3L). Five days after tumor microsurgery, locally re-
current tumor became apparent near the resection cavity
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(Fig. 3M) and was accompanied by reactive changes in the re-
section bed, including hemosiderin-laden macrophages and re-
active astrocytes (Fig. 3N–P). After 7 days, locally recurrent
tumors became large, highly mitotically active, and necrotic
(Fig. 3Q–T) and diffusely invaded the adjacent brain. Local
tumor recurrence was accompanied by increased reactive
changes in the resection bed, including infiltration of foamy
and hemosiderin-ladenmacrophages (Fig. 3U–X). These results
suggest that fluorescence-aided microsurgery in the syngeneic
TRP-mcF allograft model system recapitulates aspects of clini-
cal GBM, including invasion and distant recurrence, a process
that occurs concomitantly with reactive, surgery-induced
changes in the resection cavity.
Microsurgery Induces Dynamic Changes in the Reactive
Astrocyte Component of the Peritumoral
Microenvironment Surrounding TRP-mcF Allografts
Reactive astrocytes are the main cellular component of glial
scars that develop in response to a variety of pathological stim-
uli in the brain. During tumorigenesis, these cells play a key role
in tumor progression and invasion,13,27–30 where they develop
hypertrophic cytoplasmic processes and upregulate expression
of cytoskeletal proteins such as GFAP. Indeed, hypertrophic
GFAP+ reactive astrocytes accumulated near the invasive
edge of TRP-mcF allografts and became progressively dense
as these tumors grew (Fig. 4A and B).
In addition to tumorigenesis, reactive astrocytes are a signif-
icant component of the glial scars that develop in response to
blunt force brain trauma.31–35 In murine models, stab wound
injury induces proliferation of GFAP+ reactive astrocytes that
also express stem cell markers, such as the intermediate fila-
ment nestin.34,36 –38 Moreover, these cells have been shown
to acquire the phenotypic properties of stem cells when cul-
tured ex vivo, including unlimited self-renewal andmultilineage
differentiation.36,37 To determine whether the reactive astro-
cytes that accompanied TRP-mcF allograft growth might un-
dergo a similar change in phenotype, we performed nestin
immunostaining on established tumors. In contrast to their
abundant GFAP immunoreactivity, reactive astrocytes around
the invasive edge of TRP-mcF allografts did not express nestin,
suggesting they lacked stemlike properties (Fig. 4C).
To examine the effects of blunt force trauma induced by mi-
crosurgical resection on reactive astrocytes in the peritumoral
Fig. 1. TRP cells engineered to express mCherry and luciferase proliferate in vitro and form GBM allografts in vivo. Cultured TRP glioma cells
transduced with lentiviral vectors encoding TRP-mcF express mCherry and luciferase in vitro as determined by (A and C) white light and (B and
D) fluorescence imaging. TRP-mcF cells (doubling time 1.1 days) showed a small but statistically significant decrease in growth compared with
uninfected TRP cells (doubling time 0.9 days, P¼ .01) (E). TRP-mcF cell number showed linear correlation with Fluc activity (R2¼ .998, P,
.0001) (F). TRP-mcF allografts showed exponential growth with a doubling time of 3.3 days in vivo by BLI (G). Representative H&E staining (H
and J–M) and mCherry fluorescence imaging (I) of brain sections show large intracortical tumors 14 days after injection of TRP-mcF cells.
Tumors showed histopathological features of GBM, including microvascular proliferation (black arrowheads), an invasive brain-tumor interface
(white arrow), and elevated mitotic activity (white arrowheads). Original magnifications: 15x (H and I), 40x (A and B), 100x (C, D, and J), 200x
(K), 400x (L), and 600x (M). Scale bars, 100 mm (A–D) and 200 mm (J–M).
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microenvironment, mouse brains harvested 1–7 days after re-
section were also immunostained for GFAP and nestin. A dra-
matic decrease in the number of GFAP+ reactive astrocytes
was evident over this time course (Fig. 4D–H). Few of these
cells expressed nestin at postoperative day 1 (Fig. 4I). However,
reactive astrocytes that coexpressed both GFAP and nestin
(Fig. 4N–Q) increased 16-fold by day 3 and gradually decreased
thereafter (Fig. 4J–M). These results suggest that the blunt
force trauma induced by resection alters the reactive astrocytes
present in the peritumoral microenvironment andmay induce a
stem cell– like phenotype in these cells.36,37
Because recurrent tumors grew faster than their pre-
resection counterparts (Fig. 2H) and diffusely infiltrated the
brain (Fig. 3), we next used cell culture to explore whether as-
trocyte injury influences tumor biology in vitro. Scratch injury of
cultured astrocytes is an established in vitro model that mimics
the blunt force trauma induced by surgical resection. Cultured
astrocytes injured by scratching have been shown to undergo a
phenotypic switch to a stem cell– like state accompanied by in-
creased nestin expression.39 – 42 We confirmed that scratch
injury of immortalized astrocytes induces a 2.5-fold increase
in nestin expression within 24 h (Fig. 5A and B). Next, we exam-
ined the effects of astrocyte injury on TRP-mcF cell migration
and proliferation using a coculture system (Fig. 5C). In contrast
to the effects of uninjured astrocytes, scratch injury of immor-
talized astrocytes induced a 2.5-fold increase in migration of
cocultured TRP-mcF cells over 24 h (Fig. 5D–F). Astrocytes iso-
lated from the in vivo resection model (Supplementary Fig. S1)
increased TRP-mcF cell migration compared with uninjured as-
trocytes but showed no difference relative to injured astrocytes
(Fig. 5E). In vitro injury to astrocytes derived directly from the in
vivo model did not increase TRP-mcF migration further. Single
cell analysis (Fig. 5F) showed the TRP-mcF cells cultured with in-
jured astrocytes migrated faster (Fig. 5G), farther (Supplemen-
tary Fig. S2A), and more directly toward injured astrocytes
(Supplementary Fig. S2B) than those cultured with uninjured
astrocytes. These effects were specific to astrocyte injury, as
scratch wounding of TRP-mcF cells themselves had no effect
on their migration, in both the presence (Supplementary
Fig. S3A) and absence of injured astrocytes (Supplementary
Fig. 2. Fluorescence-guided microsurgical resection reduces volumes of orthotopic TRP-mcF allografts that redevelop to induce death. A scalp
incision (A) was made 14 days after injection of TRP-mcF cells. A craniotomy was performed (B) to visualize the underlying mCherry+ tumors
(C). Fluorescence-guided microsurgery significantly reduced tumor burden as determined by intraoperative fluorescence imaging (D).
Postoperative BLI showed a 91% reduction in mean tumor burden (N¼ 6 mice per group, P, .0001) (E). Representative BLIs pre- and
postresection are shown. Representative mCherry fluorescence (F) and H&E images (G) of brain sections taken 1 day postresection showed
residual tumor (arrows) within the resection cavity (RC). Recurrent TRP-mcF allografts (H) grew faster than their pre-resection counterparts
(data from Fig. 1G), with doubling times of 1.9 vs 3.3 days, respectively (P¼ .0003). Microsurgical resection extended survival, as resected mice
survived significantly longer than nonresected mice (31 vs 21 days, log-rank P¼ .001) (I). Fluorescence (J) and H&E images (K) of brain sections
taken 7 days postresection show recurrent tumor near the RC. Original magnifications: 15x (J and K) and 100x (F and G).
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Fig. S3B). Revealing the broad applicability of this effect, astro-
cyte injury increased migration in established GBM mouse
(GL261) and human (U251 and U87) cell lines in vitro (Fig. 5H).
To examine the effects of astrocyte injury on TRP-mcF prolif-
eration, we cocultured these cells with uninjured and injured
astrocytes and monitored their proliferation by labeling
S-phase cells with EdU. Compared with uninjured astrocytes,
scratch injury of astrocytes induced significantly more TRP-mcF
cells to enter S phase after 24 h of coculture (Fig. 5I and Supple-
mentary Fig. S4A and B). Moreover, culturing TRP-mcF cells with
the conditionedmedia of injured astrocytes increased their pro-
liferation as determined by BLI (Fig. 5J). Injured astrocytes in-
creased proliferation in both established GBM mouse and
human cell lines relative to uninjured astrocytes (Fig. 5K).
Taken together, these data suggest that the blunt force trauma
induced by surgical resection produces changes in the reactive
Fig. 3. Local and distant tumor recurrences develop following microsurgical resection of TRP-mcF allografts. Representative H&E stained sections
of mouse brains harvested 1 (A–D), 3 (E–L), 5 (M–P), and 7 (Q–X) days after resection of TRP-mcF allografts. Panels A–H show near-complete
resection of tumor around the surgical cavity. However, extensive tumor invasion was evident in the deep ipsilateral cortex (I–L) of themouse brain
shown in E–H. Panels M–X show local recurrence of tumor within the resection cavity, but the mouse brain in Q–X also shows extensive
perivascular invasion (U and V) and recurrent tumor near the ventricle (Q, arrowhead). Black arrowheads indicate the invasive brain-tumor
interface (L), reactive astrocytes (P), mitoses (J, S, and T), and foamy macrophages (W) present in recurrent tumors. White (P) and black (X)
arrowheads indicate hemosiderin-laden macrophages. Asterisk indicates necrosis (R, S, and T). Original magnifications: 40x (A, E, I, M, and Q),
100x (U), 200x (B, F, K, N, and R), 400x (C, G, H, J, O, S, W, and V), 600x (D, L, P, T, and X). Scale bars¼ 200 mm.
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microenvironment, mouse brains harvested 1–7 days after re-
section were also immunostained for GFAP and nestin. A dra-
matic decrease in the number of GFAP+ reactive astrocytes
was evident over this time course (Fig. 4D–H). Few of these
cells expressed nestin at postoperative day 1 (Fig. 4I). However,
reactive astrocytes that coexpressed both GFAP and nestin
(Fig. 4N–Q) increased 16-fold by day 3 and gradually decreased
thereafter (Fig. 4J–M). These results suggest that the blunt
force trauma induced by resection alters the reactive astrocytes
present in the peritumoral microenvironment andmay induce a
stem cell– like phenotype in these cells.36,37
Because recurrent tumors grew faster than their pre-
resection counterparts (Fig. 2H) and diffusely infiltrated the
brain (Fig. 3), we next used cell culture to explore whether as-
trocyte injury influences tumor biology in vitro. Scratch injury of
cultured astrocytes is an established in vitro model that mimics
the blunt force trauma induced by surgical resection. Cultured
astrocytes injured by scratching have been shown to undergo a
phenotypic switch to a stem cell– like state accompanied by in-
creased nestin expression.39 – 42 We confirmed that scratch
injury of immortalized astrocytes induces a 2.5-fold increase
in nestin expression within 24 h (Fig. 5A and B). Next, we exam-
ined the effects of astrocyte injury on TRP-mcF cell migration
and proliferation using a coculture system (Fig. 5C). In contrast
to the effects of uninjured astrocytes, scratch injury of immor-
talized astrocytes induced a 2.5-fold increase in migration of
cocultured TRP-mcF cells over 24 h (Fig. 5D–F). Astrocytes iso-
lated from the in vivo resection model (Supplementary Fig. S1)
increased TRP-mcF cell migration compared with uninjured as-
trocytes but showed no difference relative to injured astrocytes
(Fig. 5E). In vitro injury to astrocytes derived directly from the in
vivo model did not increase TRP-mcF migration further. Single
cell analysis (Fig. 5F) showed the TRP-mcF cells cultured with in-
jured astrocytes migrated faster (Fig. 5G), farther (Supplemen-
tary Fig. S2A), and more directly toward injured astrocytes
(Supplementary Fig. S2B) than those cultured with uninjured
astrocytes. These effects were specific to astrocyte injury, as
scratch wounding of TRP-mcF cells themselves had no effect
on their migration, in both the presence (Supplementary
Fig. S3A) and absence of injured astrocytes (Supplementary
Fig. 2. Fluorescence-guided microsurgical resection reduces volumes of orthotopic TRP-mcF allografts that redevelop to induce death. A scalp
incision (A) was made 14 days after injection of TRP-mcF cells. A craniotomy was performed (B) to visualize the underlying mCherry+ tumors
(C). Fluorescence-guided microsurgery significantly reduced tumor burden as determined by intraoperative fluorescence imaging (D).
Postoperative BLI showed a 91% reduction in mean tumor burden (N¼ 6 mice per group, P, .0001) (E). Representative BLIs pre- and
postresection are shown. Representative mCherry fluorescence (F) and H&E images (G) of brain sections taken 1 day postresection showed
residual tumor (arrows) within the resection cavity (RC). Recurrent TRP-mcF allografts (H) grew faster than their pre-resection counterparts
(data from Fig. 1G), with doubling times of 1.9 vs 3.3 days, respectively (P¼ .0003). Microsurgical resection extended survival, as resected mice
survived significantly longer than nonresected mice (31 vs 21 days, log-rank P¼ .001) (I). Fluorescence (J) and H&E images (K) of brain sections
taken 7 days postresection show recurrent tumor near the RC. Original magnifications: 15x (J and K) and 100x (F and G).
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Fig. S3B). Revealing the broad applicability of this effect, astro-
cyte injury increased migration in established GBM mouse
(GL261) and human (U251 and U87) cell lines in vitro (Fig. 5H).
To examine the effects of astrocyte injury on TRP-mcF prolif-
eration, we cocultured these cells with uninjured and injured
astrocytes and monitored their proliferation by labeling
S-phase cells with EdU. Compared with uninjured astrocytes,
scratch injury of astrocytes induced significantly more TRP-mcF
cells to enter S phase after 24 h of coculture (Fig. 5I and Supple-
mentary Fig. S4A and B). Moreover, culturing TRP-mcF cells with
the conditionedmedia of injured astrocytes increased their pro-
liferation as determined by BLI (Fig. 5J). Injured astrocytes in-
creased proliferation in both established GBM mouse and
human cell lines relative to uninjured astrocytes (Fig. 5K).
Taken together, these data suggest that the blunt force trauma
induced by surgical resection produces changes in the reactive
Fig. 3. Local and distant tumor recurrences develop following microsurgical resection of TRP-mcF allografts. Representative H&E stained sections
of mouse brains harvested 1 (A–D), 3 (E–L), 5 (M–P), and 7 (Q–X) days after resection of TRP-mcF allografts. Panels A–H show near-complete
resection of tumor around the surgical cavity. However, extensive tumor invasion was evident in the deep ipsilateral cortex (I–L) of themouse brain
shown in E–H. Panels M–X show local recurrence of tumor within the resection cavity, but the mouse brain in Q–X also shows extensive
perivascular invasion (U and V) and recurrent tumor near the ventricle (Q, arrowhead). Black arrowheads indicate the invasive brain-tumor
interface (L), reactive astrocytes (P), mitoses (J, S, and T), and foamy macrophages (W) present in recurrent tumors. White (P) and black (X)
arrowheads indicate hemosiderin-laden macrophages. Asterisk indicates necrosis (R, S, and T). Original magnifications: 40x (A, E, I, M, and Q),
100x (U), 200x (B, F, K, N, and R), 400x (C, G, H, J, O, S, W, and V), 600x (D, L, P, T, and X). Scale bars¼ 200 mm.
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astrocyte component of the peritumoral microenvironment
that may promote tumor migration and proliferation.
To identify the factors that contribute to the observed tumor
proliferation and migration induced by astrocyte injury, we per-
formed RNA-seq analysis on cultured astrocytes before and
after scratch injury. Differential gene expression analysis
(Fig. 6A) and hierarchical clustering (Fig. 6B and Supplementary
Fig. S5) revealed significant alterations to the astrocyte tran-
scriptome after scratch injury. We found that injured astrocytes
exhibited upregulation of genes involved in cytokine production
and response (Fig. 6C). Based on RNA-seq analysis, we identi-
fied 5 candidates that were upregulated and known to encode
secreted proteins (Cxcl5, Il33, Tnfsf12, Tnfsf13, and Vegfa). Four
of these candidates (Cxcl5, Il33, Tnfsf12, and Vegfa) were ex-
amined using Luminex assays, which showed that only Cxcl5
was upregulated in the supernatants of injured astrocytes
(1.42-fold, P¼ .0074; Fig. 6D). These data suggest that Cxcl5
may contribute to increased tumor proliferation and migration
following astrocyte injury.
Discussion
Surgical resection followed by radio- and chemotherapy is the
standard of care for GBM patients. Nonetheless, these treatments
ultimately fail because they are unable to reach the invasive can-
cer cells that evade surgical resection and lie outside radiation
Fig. 4. Microsurgical resection induces dynamic changes in reactive astrocytes surrounding TRP-mcF allografts. Reactive astrocytes were abundant
in the peritumoral brain parenchyma in mCherry+ (red) TRP-mcF allografts established for 7 days (A), and their density increased further in tumors
established for 14 days (B). Tumor cells, but not reactive astrocytes, expressed nestin (C). Over the course of 7 days following microsurgical tumor
resection, a gradual decrease in the density of reactive astrocytes in the peritumoral microenvironment is highlighted by GFAP immunostaining (D–
H). However, over this time course, reactive astrocytes gain expression of the stem cell marker nestin and their density peaks 3 days postresection
(I–M). Double immunostaining (N–P, merge, Q) of brains 3 days postresection shows that reactive astrocytes express both GFAP (green, O) and
nestin (red, P). Nuclei are stained with Hoechst (blue, I–L, N, and Q). All pairwise comparisons in panels H and M were significant except days 5 and
7 in (H) (P, .0001). Original magnifications: 100x. Scale bars¼ 100 mm.
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fields.10,25,26As a result, local and regional therapies that penetrate
the brain have proven effective, specifically controlled-release poly-
mers. Others, such as convection-enhanced drug delivery and cell-
based therapies, hold further promise when used as an adjunct to
surgical resection. However, their promise has yet to be clinically
realized due to the current lack of accurate preclinical models in
which to test these therapies. To address this gap, we developed
a syngeneic, immunocompetent mouse model of GBM that mim-
ics the clinical scenario of surgical resection and accurately recapit-
ulates the invasive nature of the human disease.18,20
Surgical resection remains one of the most widely used, yet
least studied components of GBM therapy. Many of the patho-
physiological events following tumor resection remain unknown,
emphasizing the need for a clinically relevant preclinical model.
Previous models have used human U87 xenografts that fail to
recapitulate important GBM features, such as brain invasion.8,9,11
In this current study, we developed a resection model that uses
glioma cells that mimic clinical hallmarks of human GBM in syn-
geneic immune-competent hosts and exhibits one of the most
important GBM features, brain invasion. This biologically faithful
Fig. 5. Astrocyte injury promotes TRP migration and proliferation in vitro. Compared with cultured, uninjured astrocytes (A), scratch wounding
induces significant increases in nestin (green) expression at 24 h (2.5-fold increase, P, .0001) (B). Astrocytes and TRP were seeded
approximately 500 mm apart and groups were constructed with and without scratch injury of each cell population (C). Time-lapse images were
captured every 20 min for 24 h and used to construct movies that revealed the migration of TPRs in real time. Injuring astrocytes by scratch
induced significantly increased migration of TRP-mcF tumor cells at 24 h (P, .0001) (D and E). Astrocytes isolated from the in vivo injury
model (ExAC uninjured) increased the migration of TRP cells (P¼ .0002) and injury in vitro (ExAC injured) did not alter migration further (P¼ .3)
(E). Single cell imaging analysis showed that injury of cocultured astrocytes (F) increased the velocity (P, .0001) (G) of individual TRP-mcF
tumor cells. Astrocyte injury induced increased migration in established GL261 (P, .0001), U251 (P, .0001), and U87 (P, .0001) GBM cell
lines (H). Compared with uninjured astrocytes, scratch injury of immortalized astrocytes increased proliferation of cocultured TRP-mcF tumor
cells 32% as measured by EdU incorporation at 24 h (P, .0001) (I). TRP-mcF cell proliferation was significantly increased when cultured in
scratch injured-astrocyte conditioned media (SACM) compared with uninjured astrocyte conditioned media (ACM) as measured by BLI
(doubling time: 1.07 vs 1.19 days, P¼ .02) (J). Scratch injury of astrocytes significantly increased proliferation of GL261 (P¼ .0006), U251 (P,
.0001), and U87 (P¼ .034) GBM cell lines (K). Original magnification: 100x. Scale bars¼ 100 mm.
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astrocyte component of the peritumoral microenvironment
that may promote tumor migration and proliferation.
To identify the factors that contribute to the observed tumor
proliferation and migration induced by astrocyte injury, we per-
formed RNA-seq analysis on cultured astrocytes before and
after scratch injury. Differential gene expression analysis
(Fig. 6A) and hierarchical clustering (Fig. 6B and Supplementary
Fig. S5) revealed significant alterations to the astrocyte tran-
scriptome after scratch injury. We found that injured astrocytes
exhibited upregulation of genes involved in cytokine production
and response (Fig. 6C). Based on RNA-seq analysis, we identi-
fied 5 candidates that were upregulated and known to encode
secreted proteins (Cxcl5, Il33, Tnfsf12, Tnfsf13, and Vegfa). Four
of these candidates (Cxcl5, Il33, Tnfsf12, and Vegfa) were ex-
amined using Luminex assays, which showed that only Cxcl5
was upregulated in the supernatants of injured astrocytes
(1.42-fold, P¼ .0074; Fig. 6D). These data suggest that Cxcl5
may contribute to increased tumor proliferation and migration
following astrocyte injury.
Discussion
Surgical resection followed by radio- and chemotherapy is the
standard of care for GBM patients. Nonetheless, these treatments
ultimately fail because they are unable to reach the invasive can-
cer cells that evade surgical resection and lie outside radiation
Fig. 4. Microsurgical resection induces dynamic changes in reactive astrocytes surrounding TRP-mcF allografts. Reactive astrocytes were abundant
in the peritumoral brain parenchyma in mCherry+ (red) TRP-mcF allografts established for 7 days (A), and their density increased further in tumors
established for 14 days (B). Tumor cells, but not reactive astrocytes, expressed nestin (C). Over the course of 7 days following microsurgical tumor
resection, a gradual decrease in the density of reactive astrocytes in the peritumoral microenvironment is highlighted by GFAP immunostaining (D–
H). However, over this time course, reactive astrocytes gain expression of the stem cell marker nestin and their density peaks 3 days postresection
(I–M). Double immunostaining (N–P, merge, Q) of brains 3 days postresection shows that reactive astrocytes express both GFAP (green, O) and
nestin (red, P). Nuclei are stained with Hoechst (blue, I–L, N, and Q). All pairwise comparisons in panels H and M were significant except days 5 and
7 in (H) (P, .0001). Original magnifications: 100x. Scale bars¼ 100 mm.
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fields.10,25,26As a result, local and regional therapies that penetrate
the brain have proven effective, specifically controlled-release poly-
mers. Others, such as convection-enhanced drug delivery and cell-
based therapies, hold further promise when used as an adjunct to
surgical resection. However, their promise has yet to be clinically
realized due to the current lack of accurate preclinical models in
which to test these therapies. To address this gap, we developed
a syngeneic, immunocompetent mouse model of GBM that mim-
ics the clinical scenario of surgical resection and accurately recapit-
ulates the invasive nature of the human disease.18,20
Surgical resection remains one of the most widely used, yet
least studied components of GBM therapy. Many of the patho-
physiological events following tumor resection remain unknown,
emphasizing the need for a clinically relevant preclinical model.
Previous models have used human U87 xenografts that fail to
recapitulate important GBM features, such as brain invasion.8,9,11
In this current study, we developed a resection model that uses
glioma cells that mimic clinical hallmarks of human GBM in syn-
geneic immune-competent hosts and exhibits one of the most
important GBM features, brain invasion. This biologically faithful
Fig. 5. Astrocyte injury promotes TRP migration and proliferation in vitro. Compared with cultured, uninjured astrocytes (A), scratch wounding
induces significant increases in nestin (green) expression at 24 h (2.5-fold increase, P, .0001) (B). Astrocytes and TRP were seeded
approximately 500 mm apart and groups were constructed with and without scratch injury of each cell population (C). Time-lapse images were
captured every 20 min for 24 h and used to construct movies that revealed the migration of TPRs in real time. Injuring astrocytes by scratch
induced significantly increased migration of TRP-mcF tumor cells at 24 h (P, .0001) (D and E). Astrocytes isolated from the in vivo injury
model (ExAC uninjured) increased the migration of TRP cells (P¼ .0002) and injury in vitro (ExAC injured) did not alter migration further (P¼ .3)
(E). Single cell imaging analysis showed that injury of cocultured astrocytes (F) increased the velocity (P, .0001) (G) of individual TRP-mcF
tumor cells. Astrocyte injury induced increased migration in established GL261 (P, .0001), U251 (P, .0001), and U87 (P, .0001) GBM cell
lines (H). Compared with uninjured astrocytes, scratch injury of immortalized astrocytes increased proliferation of cocultured TRP-mcF tumor
cells 32% as measured by EdU incorporation at 24 h (P, .0001) (I). TRP-mcF cell proliferation was significantly increased when cultured in
scratch injured-astrocyte conditioned media (SACM) compared with uninjured astrocyte conditioned media (ACM) as measured by BLI
(doubling time: 1.07 vs 1.19 days, P¼ .02) (J). Scratch injury of astrocytes significantly increased proliferation of GL261 (P¼ .0006), U251 (P,
.0001), and U87 (P¼ .034) GBM cell lines (K). Original magnification: 100x. Scale bars¼ 100 mm.
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mouse model allowed us to uncover potential mechanisms of
tumor progression following tumor resection. Thus, this resec-
tion model can help provide a better understanding of the path-
ophysiological consequences of surgical resection.
Reactive astrocytes are recruited to the local microenviron-
ment in response to an assortment of pathological stimuli,
such as tumor growth13,36,43 and blunt force trau-
ma.32,33,38,44 – 46 The pattern of reactive astrocytosis after
blunt force trauma in the CNS has been heavily studied.
After cortical stab wound injury, astrocytes react by hypertro-
phy and upregulation of nestin and GFAP, and subsequently
dedifferentiate into multipotent cells.34,36,37 Since glioma re-
section models are rare, it was unclear how reactive astrocytes
in the peritumoral microenvironmentwould react following trau-
matic brain injury induced by surgical tumor resection. We found
that reactive astrocytes express nestin following resection, sug-
gesting that these astrocytes dedifferentiate in response to sur-
gical tumor resection. One potential weakness of this study is
that we used marker expression, instead of ex vivo functional
analysis, to suggest astrocyte dedifferentiation. However, in a
similar context, reports have already shown that traumatic
brain injury causes astrocytes to acquire stem cell features, in-
cluding neurosphere formation, self-renewal, and multilineage
potential.36,37
As a prevalent component of the glioma microenvironment,
reactive astrocytes play a major role in tumor progression and
invasion.12,28,29,47,48 Since our data suggest that these astro-
cytes dedifferentiate in response to surgical resection, we fur-
ther extended these findings by investigating how this
response may influence tumor biology, specifically tumor
growth and migration. Using an in vitro model that mimics
the in vivo astrocyte response to injury,39–42,49 we found that
the astrocyte response promotes tumor proliferation and mi-
gration, suggesting that reactive astrocytes may potentiate
tumor aggressiveness after resection. Moreover, we found
that recurrent tumors are highly invasive and exhibited signifi-
cantly faster growth compared with their nonresected counter-
parts. Since in vitro tumor growth showed a marginal increase
compared with the in vivo response, this suggests that reactive
astrocytes may be only a contributing factor in promotion of
the increased proliferation of recurrent tumors. Although
tumor growth and proliferation are more straightforward to
monitor, it is difficult to assess in vivo tumor invasion due to
mass effects from the malignant tumor. Therefore, surgical
tumor resection provided a unique opportunity to study
tumor cell invasion. While it is challenging to compare the inva-
sion of pre- versus postoperative tumors, we found that recur-
rent tumors extensively invaded the brain. Moreover, surgical
intervention alters the reactive astrocyte composition within
the tumor microenvironment and may have deleterious conse-
quences on patient survival. While glioma resection remains
the standard of care in qualified patients, this report highlights
Fig. 6. Astrocyte injury induces transcriptome and secretome changes. Differential expression analysis (A) and hierarchical clustering showed that
scratch injury of astrocytes (S1–S4) induced significant transcriptome alterations (2093 genes, q, 0.001) compared with uninjured (C1–C4)
astrocytes (B). Ontology analysis of upregulated genes revealed enrichment in genes associated with cytokine production and response (C).
Compared with uninjured astrocytes, astrocyte injury increased secretion of Cxcl5 (P¼ .0074) (D) as measured by Luminex analysis.
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the role of reactive astrocytes in inducing a more favorable mi-
croenvironment for tumor regrowth and recurrence. This sug-
gests that our model may provide the means to further
understand how the postsurgical microenvironment influences
tumor properties and allows for the development of drugs to
combat resection-mediated effects. Our data suggest that
Cxcl5 contributes to increased tumor invasion and proliferation
after GBM resection, but further experimentation is needed to
fully characterize and identify the factors responsible for in
vivo response. We are currently exploring these molecular
mechanisms.
Microglia/macrophages are likely to play an important role in
the postsurgical microenvironment as tissue scavengers and
may potentiate the aggressiveness of recurrent tumors.13,50,51
These cells have been implicated in glioma pathogenesis and
may promote a tumor-permissive microenvironment.52–54 We
found that recurrent tumors exhibited a significant increase in
Iba-1+ cells in the tumor compared with pre-resection (Supple-
mentary Fig. S6). This suggests that microglia/macrophages
may play a role in the increased tumor migration and/or prolif-
eration observed after resection.
Surgery alters the tumor microenvironment, which is largely
composed of reactive astrocytes. The microenvironment in es-
tablished nonresected tumors contains a high tumor-to–reac-
tive astrocyte ratio, while, after tumor resection, recurrent
tumors harbor a much lower proportion. Though surgery ma-
nipulates themicroenvironment, it remains unclear how this af-
fects local treatment strategies such as stem cell therapies.
Engineered stem cells extensively home to glioma cells and
have shown therapeutic efficacy55,56—though, in a similar con-
text, implanting stem cells within a CNS lesion has been shown
to reduce stem cell survival, alter differentiation, and decrease
therapeutic efficacy.9,57 However, the molecular mechanism
and signals associated with this response remain unclear. To
better develop stem cell therapies, we are currently investigat-
ing the underlying mechanisms that reduce stem cell efficacy
in the postsurgical tumor microenvironment.
In conclusion, our study demonstrates the development of a
new glioma resection model in syngeneic immune-competent
hosts that allowed us to study the postsurgical microenviron-
ment and pattern of tumor recurrence. We found that surgical
resection alters the reactive astrocyte component of the peritu-
moral microenvironment and that injured astrocytes may sig-
nificantly influence tumor biology. Using this study as a
template, more investigations can be conducted to gain a bet-
ter understanding of the postsurgical microenvironment. This
will allow optimization of locally administered therapies and fa-
cilitate the development of agents that ameliorate surgery-
mediated effects on tumor properties.
Supplementary Material
Supplementary material is available at Neuro-Oncology Journal
online (http://neuro-oncology.oxfordjournals.org/).
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mouse model allowed us to uncover potential mechanisms of
tumor progression following tumor resection. Thus, this resec-
tion model can help provide a better understanding of the path-
ophysiological consequences of surgical resection.
Reactive astrocytes are recruited to the local microenviron-
ment in response to an assortment of pathological stimuli,
such as tumor growth13,36,43 and blunt force trau-
ma.32,33,38,44 – 46 The pattern of reactive astrocytosis after
blunt force trauma in the CNS has been heavily studied.
After cortical stab wound injury, astrocytes react by hypertro-
phy and upregulation of nestin and GFAP, and subsequently
dedifferentiate into multipotent cells.34,36,37 Since glioma re-
section models are rare, it was unclear how reactive astrocytes
in the peritumoral microenvironmentwould react following trau-
matic brain injury induced by surgical tumor resection. We found
that reactive astrocytes express nestin following resection, sug-
gesting that these astrocytes dedifferentiate in response to sur-
gical tumor resection. One potential weakness of this study is
that we used marker expression, instead of ex vivo functional
analysis, to suggest astrocyte dedifferentiation. However, in a
similar context, reports have already shown that traumatic
brain injury causes astrocytes to acquire stem cell features, in-
cluding neurosphere formation, self-renewal, and multilineage
potential.36,37
As a prevalent component of the glioma microenvironment,
reactive astrocytes play a major role in tumor progression and
invasion.12,28,29,47,48 Since our data suggest that these astro-
cytes dedifferentiate in response to surgical resection, we fur-
ther extended these findings by investigating how this
response may influence tumor biology, specifically tumor
growth and migration. Using an in vitro model that mimics
the in vivo astrocyte response to injury,39–42,49 we found that
the astrocyte response promotes tumor proliferation and mi-
gration, suggesting that reactive astrocytes may potentiate
tumor aggressiveness after resection. Moreover, we found
that recurrent tumors are highly invasive and exhibited signifi-
cantly faster growth compared with their nonresected counter-
parts. Since in vitro tumor growth showed a marginal increase
compared with the in vivo response, this suggests that reactive
astrocytes may be only a contributing factor in promotion of
the increased proliferation of recurrent tumors. Although
tumor growth and proliferation are more straightforward to
monitor, it is difficult to assess in vivo tumor invasion due to
mass effects from the malignant tumor. Therefore, surgical
tumor resection provided a unique opportunity to study
tumor cell invasion. While it is challenging to compare the inva-
sion of pre- versus postoperative tumors, we found that recur-
rent tumors extensively invaded the brain. Moreover, surgical
intervention alters the reactive astrocyte composition within
the tumor microenvironment and may have deleterious conse-
quences on patient survival. While glioma resection remains
the standard of care in qualified patients, this report highlights
Fig. 6. Astrocyte injury induces transcriptome and secretome changes. Differential expression analysis (A) and hierarchical clustering showed that
scratch injury of astrocytes (S1–S4) induced significant transcriptome alterations (2093 genes, q, 0.001) compared with uninjured (C1–C4)
astrocytes (B). Ontology analysis of upregulated genes revealed enrichment in genes associated with cytokine production and response (C).
Compared with uninjured astrocytes, astrocyte injury increased secretion of Cxcl5 (P¼ .0074) (D) as measured by Luminex analysis.
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the role of reactive astrocytes in inducing a more favorable mi-
croenvironment for tumor regrowth and recurrence. This sug-
gests that our model may provide the means to further
understand how the postsurgical microenvironment influences
tumor properties and allows for the development of drugs to
combat resection-mediated effects. Our data suggest that
Cxcl5 contributes to increased tumor invasion and proliferation
after GBM resection, but further experimentation is needed to
fully characterize and identify the factors responsible for in
vivo response. We are currently exploring these molecular
mechanisms.
Microglia/macrophages are likely to play an important role in
the postsurgical microenvironment as tissue scavengers and
may potentiate the aggressiveness of recurrent tumors.13,50,51
These cells have been implicated in glioma pathogenesis and
may promote a tumor-permissive microenvironment.52–54 We
found that recurrent tumors exhibited a significant increase in
Iba-1+ cells in the tumor compared with pre-resection (Supple-
mentary Fig. S6). This suggests that microglia/macrophages
may play a role in the increased tumor migration and/or prolif-
eration observed after resection.
Surgery alters the tumor microenvironment, which is largely
composed of reactive astrocytes. The microenvironment in es-
tablished nonresected tumors contains a high tumor-to–reac-
tive astrocyte ratio, while, after tumor resection, recurrent
tumors harbor a much lower proportion. Though surgery ma-
nipulates themicroenvironment, it remains unclear how this af-
fects local treatment strategies such as stem cell therapies.
Engineered stem cells extensively home to glioma cells and
have shown therapeutic efficacy55,56—though, in a similar con-
text, implanting stem cells within a CNS lesion has been shown
to reduce stem cell survival, alter differentiation, and decrease
therapeutic efficacy.9,57 However, the molecular mechanism
and signals associated with this response remain unclear. To
better develop stem cell therapies, we are currently investigat-
ing the underlying mechanisms that reduce stem cell efficacy
in the postsurgical tumor microenvironment.
In conclusion, our study demonstrates the development of a
new glioma resection model in syngeneic immune-competent
hosts that allowed us to study the postsurgical microenviron-
ment and pattern of tumor recurrence. We found that surgical
resection alters the reactive astrocyte component of the peritu-
moral microenvironment and that injured astrocytes may sig-
nificantly influence tumor biology. Using this study as a
template, more investigations can be conducted to gain a bet-
ter understanding of the postsurgical microenvironment. This
will allow optimization of locally administered therapies and fa-
cilitate the development of agents that ameliorate surgery-
mediated effects on tumor properties.
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